Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2000
Size (employees)
294 (est)
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

Merrimack Pharmaceuticals Data and Metrics

Merrimack Pharmaceuticals Financial Metrics

Merrimack Pharmaceuticals's revenue was reported to be $144.3 m in FY, 2016
USD

Net income (Q1, 2017)

(30.2 m)

Market capitalization (19-Sep-2017)

192.3 m

Cash (31-Mar-2017)

17.2 m
Merrimack Pharmaceuticals's current market capitalization is $192.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

47.8 m102.8 m89.3 m144.3 m

Revenue growth, %

115%(13%)62%

Cost of goods sold

6.9 m

Gross profit

137.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

21.3 m33.7 m28.1 m

Cost of goods sold

1.9 m1 m

Gross profit

31.8 m27.1 m

Gross profit Margin, %

94%96%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

65.1 m35.7 m185.6 m21.5 m

Accounts Receivable

5.9 m3.3 m6.5 m17.5 m

Inventories

5.5 m4.7 m5.5 m14.6 m

Current Assets

166.6 m132.1 m201.4 m57.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

77.8 m100.3 m28.8 m33.7 m56.4 m48.2 m21.5 m36.5 m17.2 m

Accounts Receivable

6.6 m2.6 m4.2 m1.8 m2.1 m15.6 m19.3 m22.2 m43 k

Inventories

8.1 m12.3 m14.8 m

Current Assets

103.8 m162.1 m99.3 m74.9 m70.9 m160.7 m119 m89.6 m46.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(130.7 m)(83.6 m)(147.8 m)(153.5 m)

Depreciation and Amortization

2.6 m3.2 m4.3 m6.2 m

Accounts Receivable

3.4 m2.6 m(3.2 m)(11 m)

Inventories

4 m827 k(850 k)(9.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.3 m)(28 m)(34.4 m)(22.9 m)(42.4 m)(38.7 m)(51 m)(30.3 m)(30.2 m)

Accounts Receivable

6.6 m2.6 m4.2 m1.8 m2.1 m15.6 m19.3 m22.2 m43 k

Inventories

8.1 m12.3 m14.8 m
Show all financial metrics

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Median Salaries

Source: 20 public H-1B filings from Merrimack Pharmaceuticals

Traffic Overview of Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Online and Social Media Presence

Merrimack Pharmaceuticals News and Updates

US Stocks Modestly Lower in Early Trading; Oil Prices Slide

U.S. stock indexes edged mostly lower in early trading Monday, led by declines in energy companies. Oil and gas companies fell the most as the price of crude oil headed lower. Materials stocks notched the biggest gain. Investors had their eye on the latest company earnings and deal news.

Boston Vs. NYC Vs. LA Exits: New York Wins On Quantity, LA On Big Winners

Outside of Silicon Valley, New York has seen the most venture-backed companies exit since 2012, over Boston and Los Angeles. In fact, nearly half, 44%, of all the exits in the three cities over the last five years were for … Continued

Wall St. Is Down as Health Stocks Slide

Shares of Merrimack Pharmaceuticals fell after the company said it would cut almost a quarter of its work force and would look for a new chief executive.

Merrimack Pharmaceuticals Company Life and Culture

You may also be interested in